2bve: Difference between revisions

From Proteopedia
Jump to navigationJump to search
OCA (talk | contribs)
No edit summary
OCA (talk | contribs)
No edit summary
Line 5: Line 5:


==Overview==
==Overview==
The Siglec family of receptors mediates cell-surface interactions through, recognition of sialylated glycoconjugates. Previously reported structures, of the N-terminal domain of the Siglec sialoadhesin (SnD1) in complex with, various sialic acid analogs revealed the structural template for sialic, acid binding. To characterize further the carbohydrate-binding properties, we have determined the crystal structures of SnD1 in the absence of, ligand, and in complex with 2-benzyl-Neu5NPro and 2-benzyl-Neu5NAc. These, structures reveal that SnD1 undergoes very few structural changes on, ligand binding and detail how two novel classes of sialic acid analogs, bind, one of which unexpectedly can induce Siglec dimerization. In, conjunction with in silico analysis, this set of structures informs us, ... [[http://ispc.weizmann.ac.il/pmbin/getpm?17137591 (full description)]]
The Siglec family of receptors mediates cell-surface interactions through, recognition of sialylated glycoconjugates. Previously reported structures, of the N-terminal domain of the Siglec sialoadhesin (SnD1) in complex with, various sialic acid analogs revealed the structural template for sialic, acid binding. To characterize further the carbohydrate-binding properties, we have determined the crystal structures of SnD1 in the absence of, ligand, and in complex with 2-benzyl-Neu5NPro and 2-benzyl-Neu5NAc. These, structures reveal that SnD1 undergoes very few structural changes on, ligand binding and detail how two novel classes of sialic acid analogs, bind, one of which unexpectedly can induce Siglec dimerization. In, conjunction with in silico analysis, this set of structures informs us, about the design of putative ligands with enhanced binding affinities and, specificities to different Siglecs, and provides data with which to test, the effectiveness of different computational drug design protocols.


==About this Structure==
==About this Structure==
2BVE is a [[http://en.wikipedia.org/wiki/Single_protein Single protein]] structure of sequence from [[http://en.wikipedia.org/wiki/Mus_musculus Mus musculus]] with PH5 as [[http://en.wikipedia.org/wiki/ligand ligand]]. Structure known Active Site: AC1. Full crystallographic information is available from [[http://ispc.weizmann.ac.il/oca-bin/ocashort?id=2BVE OCA]].  
2BVE is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Mus_musculus Mus musculus] with PH5 as [http://en.wikipedia.org/wiki/ligand ligand]. Structure known Active Site: AC1. Full crystallographic information is available from [http://ispc.weizmann.ac.il/oca-bin/ocashort?id=2BVE OCA].  


==Reference==
==Reference==
Line 30: Line 30:
[[Category: siglec]]
[[Category: siglec]]


''Page seeded by [http://ispc.weizmann.ac.il/oca OCA ] on Tue Oct 30 16:49:09 2007''
''Page seeded by [http://ispc.weizmann.ac.il/oca OCA ] on Mon Nov  5 14:25:04 2007''